What about Beijing Han Shi United Biotechnology Co., Ltd.? Is it reliable?

Hanlian has a professional research team under the direct leadership of the director of the National Stem Cell Research Center, and the director of the National Stem Cell Research Center is the chairman. Is a trustworthy enterprise, with very strong strength and professional technology. Han is also a foreign academician of the French Academy of Medical Sciences and the French National Institute of Technology, and enjoys a high reputation internationally. At the same time, Han cooperated with French Academy of Medical Sciences, Shi Weiya, Institute of Hematology of China Academy of Medical Sciences, Shandong Academy of Medical Sciences, Henan Cancer Hospital, Medical College of Jinan University, School of Life Sciences of Beijing Jiaotong University, Guiyang Medical College, Kunming Medical College, Jiangsu Provincial Hospital, Fujian Medical University, An Gaoxin Hospital and Jiangxi Medical College.

From March 2065438 to March 2004, placental hematopoietic stem cells and related technologies were provided by Hanlian Biotechnology Co., Ltd., and the team of the 307th Hospital of the People's Liberation Army successfully performed hematopoietic stem cell transplantation to treat severe aplastic anemia.

It is understood that in the past two years, while stabilizing the domestic market, Hanlian is also constantly exploring the international market. Domestically, there are 17 subsidiaries in China. Abroad, we have set up subsidiaries in France and South Korea. In the aspect of medical transformation of stem cell technology, the safety evaluation and pharmacodynamic experiment of placental mesenchymal stem cells designed by Korea in accordance with American and European standards are fully qualified to apply for clinical trials in EU countries and the United States. It is reported that Han United is the first enterprise in China to obtain the application qualification. In addition, Han's combination with a variety of stem cell drugs is under research and development and clinical research, and is preparing to apply for new clinical trials of stem cell drugs in China, France, the United States and South Korea.